Compare SELLAS Life Sciences Group Inc. Common Stock (SLS) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SELLAS Life Sciences Group Inc. Common Stock vs 10X Genomics Inc — how do they compare? SELLAS Life Sciences Group Inc. Common Stock trades at $11.24 (market cap $2.28B), while 10X Genomics Inc trades at $80 (market cap $9.92B). The key difference: 10X Genomics Inc is far larger — about 4.4× SELLAS Life Sciences Group Inc. Common Stock's market cap, and 10X Genomics Inc is more actively traded (9,372,166 versus 3,128,960). Which is the better fit depends on your goals.
| SLS | TXG | |
|---|---|---|
Market Cap | $2.28B | $9.92B |
Volume | 3,128,960 | 9,372,166 |
Sector | Health | Health |
52-Week High | $15.46 | $97.74 |
52-Week Low | $1.39 | $11.48 |
Enterprise Value | $2.15B | $9.44B |
Typical Hold Time | — | 92 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
10x Genomics (TXG) trades at $77.28, down 4.19% on the day, amid a bearish technical signal. The company reported revenue of $642.82M in 2025, with a net loss of $43.54M, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights the launch of its Atera spatial biology platform and a patent victory, signaling innovation and market strength. Cash flow from operations improved to $136.05M in 2025, indicating better operational efficiency.
The outlook is cautiously optimistic, with strong product demand and improving margins offering upside potential. However, persistent losses, high valuation multiples, and competitive pressures present significant risks. Analyst consensus is mixed, with a $74.30 price target slightly below the current price, reflecting uncertainty about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
